Skip to main content

Specialty Pharmacy

  • Genoa acquires Advanced Care’s behavioral health, residential care services

    TUKWILA, Wash. — Genoa on Thursday announced that it would be acquiring Advanced Care’s Behavioral Health and Residential Care Services Division, including 13 pharmacies in Michigan. The acquisition raises the number of Genoa pharmacies in Michigan to 24, with more than 325 nationally, most of which are located onsite at community mental health centers.
     

  • Mayne Pharma acquires dermatology foam portfolio from GSK

    GREENVILLE, N.C. — Mayne Pharma on Thursday announced that it had acquired a portfolio of dermatology foam products from GSK in $50.1 million deal. Among the portfolio’s products are U.S. rights to acne treatment Fabior (tazarotene) foam and plaque psoriasis treatment Sorilux (calcipotriene) foam. The company also gains the Canadian rights to Luxiq and Olux-E, as well as Mexican rights to betamethasone foam. 
     

  • Report: New, promising osteoporosis drug nears approval

  • Diplomat to dispense Zinbryta

    FLINT, Mich. — Diplomat Pharmacy announced Monday that it is now filling prescriptions for the recently approved Zinbryta (daclizumab), a drug to treat relapsing forms of multiple sclerosis. The drug is generally reserved for patients with inadequate responses to two or more MS therapies. 
     
    “A relapse of any kind can cause a person to lose hope,” Diplomat president Gary Kadlec said. “For people with relapsing multiple sclerosis, Zinbryta has the potential to restore that hope and make life a little easier.”

  • Mediware releases CareTrend for specialty pharmacies

    LENEXA, Kan. — Healthcare software company Mediware Information Systems announced Wednesday that its CareTrend platform is now available for specialty pharmacies. The new platform looks to simplify prescription procession, pharmacy workflow, reimbursement and reporting. 
     

  • Diplomat reports Q2 results, including 35% total revenue gain

    FLINT, Mich. — Diplomat Pharmacy on Tuesday announced the results of its second quarter, reporting total revenue of $1.09 billion, a 35% increase over the same quarter in 2015. 
     

  • Report: CVS formulary to swap Neupogen, Lantus for biosimilars next year

  • Specialty drives double-digit growth

    For the second year in a row, spending on medicines in 2015 grew by double-digits, increasing 12.2% on an invoice basis to $424.8 billion, according to the IMS Institute for Healthcare Informatics’ medicine report on spending for 2015.

X
This ad will auto-close in 10 seconds